Literature DB >> 28657320

Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.

Jian Min, Valeria Sanabria Guillen, Abhishek Sharma, Yuechao Zhao, Yvonne Ziegler, Ping Gong, Christopher G Mayne, Sathish Srinivasan1, Sung Hoon Kim, Kathryn E Carlson, Kendall W Nettles1, Benita S Katzenellenbogen, John A Katzenellenbogen.   

Abstract

To search for new antiestrogens more effective in treating breast cancers, we explored alternatives to the acrylic acid side chain used in many antiestrogens. To facilitate our search, we used a simple adamantyl ligand core that by avoiding stereochemical issues enabled rapid synthesis of acrylate ketone, ester, and amide analogs. All compounds were high affinity estrogen receptor α (ERα) ligands but displayed a range of efficacies and potencies as antiproliferative and ERα-downregulating agents. There were large differences in activity between compounds having minor structural changes, but antiproliferative and ERα-downregulating efficacies generally paralleled one another. Some compounds with side chain polar groups had particularly high affinities. The secondary carboxamides had the best cellular activities, and the 3-hydroxypropylamide was as efficacious as fulvestrant in suppressing cell proliferation and gene expression. This study has produced structurally novel antiestrogens based on a simple adamantyl core structure with acrylate side chains optimized for cellular antagonist activity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28657320      PMCID: PMC6039301          DOI: 10.1021/acs.jmedchem.7b00585

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  50 in total

1.  Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.

Authors:  Sébastien L Degorce; Andrew Bailey; Rowena Callis; Chris De Savi; Richard Ducray; Gillian Lamont; Philip MacFaul; Mickael Maudet; Scott Martin; Rémy Morgentin; Richard A Norman; Aurélien Peru; Jennifer H Pink; Patrick A Plé; Bryan Roberts; James S Scott
Journal:  J Med Chem       Date:  2015-04-01       Impact factor: 7.446

2.  3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats.

Authors:  T M Willson; B R Henke; T M Momtahen; P S Charifson; K W Batchelor; D B Lubahn; L B Moore; B B Oliver; H R Sauls; J A Triantafillou
Journal:  J Med Chem       Date:  1994-05-27       Impact factor: 7.446

3.  The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.

Authors:  Suzanne E Wardell; Jeffrey R Marks; Donald P McDonnell
Journal:  Biochem Pharmacol       Date:  2011-04-09       Impact factor: 5.858

4.  Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.

Authors:  Jonna Frasor; Edmund C Chang; Barry Komm; Chin-Yo Lin; Vinsensius B Vega; Edison T Liu; Lance D Miller; Johanna Smeds; Jonas Bergh; Benita S Katzenellenbogen
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

5.  Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).

Authors:  Jiawang Liu; Shilong Zheng; Victoria L Akerstrom; Chester Yuan; Youning Ma; Qiu Zhong; Changde Zhang; Qiang Zhang; Shanchun Guo; Peng Ma; Elena V Skripnikova; Melyssa R Bratton; Antonio Pannuti; Lucio Miele; Thomas E Wiese; Guangdi Wang
Journal:  J Med Chem       Date:  2016-08-29       Impact factor: 7.446

6.  Bridged bicyclic cores containing a 1,1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor.

Authors:  Rajeev S Muthyala; Shubin Sheng; Kathryn E Carlson; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2003-04-24       Impact factor: 7.446

7.  Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.

Authors:  Peilu Wang; Amir Bahreini; Rekha Gyanchandani; Peter C Lucas; Ryan J Hartmaier; Rebecca J Watters; Amruth R Jonnalagadda; Humberto E Trejo Bittar; Aaron Berg; Ronald L Hamilton; Brenda F Kurland; Kurt R Weiss; Aju Mathew; Jose Pablo Leone; Nancy E Davidson; Marina N Nikiforova; Adam M Brufsky; Tadeu F Ambros; Andrew M Stern; Shannon L Puhalla; Adrian V Lee; Steffi Oesterreich
Journal:  Clin Cancer Res       Date:  2015-10-23       Impact factor: 12.531

8.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype.

Authors:  Jonna Frasor; Jeanne M Danes; Barry Komm; Ken C N Chang; C Richard Lyttle; Benita S Katzenellenbogen
Journal:  Endocrinology       Date:  2003-07-10       Impact factor: 4.736

9.  Full antagonism of the estrogen receptor without a prototypical ligand side chain.

Authors:  Sathish Srinivasan; Jerome C Nwachukwu; Nelson E Bruno; Venkatasubramanian Dharmarajan; Devrishi Goswami; Irida Kastrati; Scott Novick; Jason Nowak; Valerie Cavett; Hai-Bing Zhou; Nittaya Boonmuen; Yuechao Zhao; Jian Min; Jonna Frasor; Benita S Katzenellenbogen; Patrick R Griffin; John A Katzenellenbogen; Kendall W Nettles
Journal:  Nat Chem Biol       Date:  2016-11-21       Impact factor: 15.040

10.  ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Authors:  Weiyi Toy; Yang Shen; Helen Won; Bradley Green; Rita A Sakr; Marie Will; Zhiqiang Li; Kinisha Gala; Sean Fanning; Tari A King; Clifford Hudis; David Chen; Tetiana Taran; Gabriel Hortobagyi; Geoffrey Greene; Michael Berger; José Baselga; Sarat Chandarlapaty
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

View more
  7 in total

1.  Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.

Authors:  Abhishek Sharma; Weiyi Toy; Valeria Sanabria Guillen; Naina Sharma; Jian Min; Kathryn E Carlson; Christopher G Mayne; Shengjia Lin; Michael Sabio; Geoffrey Greene; Benita S Katzenellenbogen; Sarat Chandarlapaty; John A Katzenellenbogen
Journal:  ACS Chem Biol       Date:  2018-11-26       Impact factor: 5.100

2.  Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.

Authors:  Mary J Laws; Yvonne Ziegler; Sayyed Hamed Shahoei; Parama Dey; Sung Hoon Kim; Mayuri Yasuda; Ben Ho Park; Kendall W Nettles; John A Katzenellenbogen; Erik R Nelson; Benita S Katzenellenbogen
Journal:  Breast Cancer Res Treat       Date:  2020-04-10       Impact factor: 4.872

Review 3.  Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.

Authors:  John A Katzenellenbogen; Christopher G Mayne; Benita S Katzenellenbogen; Geoffrey L Greene; Sarat Chandarlapaty
Journal:  Nat Rev Cancer       Date:  2018-06       Impact factor: 60.716

4.  New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.

Authors:  Lucia Wang; Valeria S Guillen; Naina Sharma; Kevin Flessa; Jian Min; Kathryn E Carlson; Weiyi Toy; Sara Braqi; Benita S Katzenellenbogen; John A Katzenellenbogen; Sarat Chandarlapaty; Abhishek Sharma
Journal:  ACS Med Chem Lett       Date:  2018-07-05       Impact factor: 4.345

Review 5.  Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.

Authors:  Irshad Ahmad; Shimy Mathew; Sofia Rahman
Journal:  RSC Med Chem       Date:  2020-03-06

6.  Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.

Authors:  Yuechao Zhao; Mary J Laws; Valeria Sanabria Guillen; Yvonne Ziegler; Jian Min; Abhishek Sharma; Sung Hoon Kim; David Chu; Ben Ho Park; Steffi Oesterreich; Chengjian Mao; David J Shapiro; Kendall W Nettles; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

7.  Probing the Effect of Halogen Substituents (Br, Cl, and F) on the Non-covalent Interactions in 1-(Adamantan-1-yl)-3-arylthiourea Derivatives: A Theoretical Study.

Authors:  Lamya H Al-Wahaibi; Divya Sri Grandhi; Samar S Tawfik; Nora H Al-Shaalan; Mohammed A Elmorsy; Ali A El-Emam; M Judith Percino; Subbiah Thamotharan
Journal:  ACS Omega       Date:  2021-02-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.